At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 9, 2026 at 07:00 ET
Turn Therapeutics reported a net loss of $6.2M for Q3 2026, wider than the $1.9M loss in Q3 2025, driven by a $3.3M non-cash derivative liability charge. The company highlighted positive Phase 2a data for GX-03 in atopic dermatitis and accelerated its HS trial, but remains a pre-revenue clinical-stage biotech with $10.4M cash funding operations into Q3 2027.
- Net loss for Q3 2026 was $6.2M ($0.21 per share) vs $1.9M ($0.07) in Q3 2025
- Cash and cash equivalents of $10.4M as of September 30, 2026, expected to fund operations into Q3 2027
- GX-03 Phase 2a atopic dermatitis trial: 59.3% of patients achieved clear/almost clear skin at 4 weeks vs 30.4% vehicle
- Phase 2b atopic dermatitis trial ongoing, topline results expected Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access